Payment overview · 2025
General Payments
$173.78
10 reported records · 5 companies
Healthcare provider profile · identity verified
Kristi G. Sutton, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BRYANT, AR · NPI 1720202989
Verified facts
What the public records show
CMS Open Payments records show Kristi G. Sutton, MD received $173.78 in general payments during 2025 across 10 reported records.
PFIZER INC. accounted for 32.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Gemtesa, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 189 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $55.85 | 32.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $52.08 | 30.0% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $30.14 | 17.3% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $20.41 | 11.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.30 | 8.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $173.78 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $55.85 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $42.08 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $34.26 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $34.26 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $30.14 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $20.41 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.63 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $13.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 189 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 136 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
110 | 34 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
136 | 36 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
189 | 45 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 890 | 241 |
| Atorvastatin Calcium | Atorvastatin Calcium | 816 | 258 |
| Losartan Potassium | Losartan Potassium | 701 | 207 |
| Pravastatin Sodium | Pravastatin Sodium | 637 | 204 |
| Lisinopril | Lisinopril | 573 | 186 |
| Tramadol Hcl | Tramadol Hcl | 513 | 109 |
| Omeprazole | Omeprazole | 421 | 156 |
| Amlodipine Besylate | Amlodipine Besylate | 415 | 133 |
| Trazodone Hcl | Trazodone Hcl | 356 | 129 |
| Sertraline Hcl | Sertraline Hcl | 332 | 90 |
| Famotidine | Famotidine | 328 | 124 |
| Gabapentin | Gabapentin | 308 | 103 |
| Simvastatin | Simvastatin | 295 | 87 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 264 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 255 | 81 |
| Doxazosin Mesylate | Doxazosin Mesylate | 239 | 68 |
| Furosemide | Furosemide | 238 | 86 |
| Metoprolol Tartrate | Metoprolol Tartrate | 231 | 80 |
| Memantine Hcl | Memantine Hcl | 219 | 52 |
| Metformin Hcl | Metformin Hcl | 218 | 73 |
| Metoprolol Succinate | Metoprolol Succinate | 208 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 194 | 70 |
| Hydrochlorothiazide | Hydrochlorothiazide | 192 | 71 |
| Meloxicam | Meloxicam | 192 | 69 |
| Eliquis | Apixaban | 189 | 45 |
| Potassium Chloride | Potassium Chloride | 189 | 70 |
| Celecoxib | Celecoxib | 185 | 68 |
| Allopurinol | Allopurinol | 175 | 48 |
| Donepezil Hcl | Donepezil Hcl | 175 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 175 | 55 |
| Carvedilol | Carvedilol | 170 | 51 |
| Montelukast Sodium | Montelukast Sodium | 166 | 56 |
| Lorazepam | Lorazepam | 147 | 34 |
| Ozempic | Semaglutide | 136 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 127 | 57 |
| Temazepam | Temazepam | 126 | 43 |
| Alendronate Sodium | Alendronate Sodium | 121 | 40 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 121 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 112 | 38 |
| Synthroid | Levothyroxine Sodium | 110 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 107 | 49 |
| Baclofen | Baclofen | 106 | 28 |
| Buspirone Hcl | Buspirone Hcl | 104 | 42 |
| Atenolol | Atenolol | 102 | 30 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 101 | 34 |
| Estradiol | Estradiol | 98 | 38 |
| Citalopram Hbr | Citalopram Hydrobromide | 97 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 97 | 35 |
| Ezetimibe | Ezetimibe | 96 | 36 |
| Topiramate | Topiramate | 95 | 36 |
| Fenofibrate | Fenofibrate | 94 | 28 |
| Clonazepam | Clonazepam | 90 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 90 | 31 |
| Oxybutynin Chloride | Oxybutynin Chloride | 83 | 32 |
| Bupropion Hcl Sr | Bupropion Hcl | 81 | 35 |
| Metformin Hcl Er | Metformin Hcl | 80 | 22 |
| Lovastatin | Lovastatin | 75 | 19 |
| Glimepiride | Glimepiride | 73 | 24 |
| Diazepam | Diazepam | 72 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 69 | 35 |
| Fluoxetine Hcl | Fluoxetine Hcl | 67 | 22 |
| Ibandronate Sodium | Ibandronate Sodium | 66 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 65 | 20 |
| Mirtazapine | Mirtazapine | 64 | 20 |
| Primidone | Primidone | 64 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 60 | 32 |
| Doxycycline Hyclate | Doxycycline Hyclate | 60 | 52 |
| Xarelto | Rivaroxaban | 60 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 59 | 21 |
| Propranolol Hcl | Propranolol Hcl | 59 | 16 |
| Finasteride | Finasteride | 58 | 22 |
| Glipizide | Glipizide | 58 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 58 | 30 |
| Rivastigmine | Rivastigmine Tartrate | 57 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 54 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 54 | 18 |
| Pregabalin | Pregabalin | 51 | 19 |
| Bupropion Xl | Bupropion Hcl | 50 | 18 |
| Prednisone | Prednisone | 50 | 25 |
| Benazepril Hcl | Benazepril Hcl | 49 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 49 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 47 | 45 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 47 | 17 |
| Spironolactone | Spironolactone | 47 | 16 |
| Warfarin Sodium | Warfarin Sodium | 47 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 44 | suppressed |
| Nifedipine Er | Nifedipine | 44 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 43 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 43 | 13 |
| Cholestyramine | Cholestyramine (With Sugar) | 42 | 15 |
| Valsartan | Valsartan | 42 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 38 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 38 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 27 |
| Valacyclovir | Valacyclovir Hcl | 36 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | 11 |
| Raloxifene Hcl | Raloxifene Hcl | 35 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | 12 |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | 12 |
| Propafenone Hcl | Propafenone Hcl | 33 | suppressed |
| Irbesartan | Irbesartan | 32 | 11 |
| Methylprednisolone | Methylprednisolone | 32 | 30 |
| Midodrine Hcl | Midodrine Hcl | 32 | 12 |
| Lansoprazole | Lansoprazole | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 26 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 13 |
| Armour Thyroid | Thyroid,pork | 23 | suppressed |
| Gemtesa | Vibegron | 23 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 23 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Gemfibrozil | Gemfibrozil | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 20 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 17 |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | 12 |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Anastrozole | Anastrozole | 16 | suppressed |
| Armodafinil | Armodafinil | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Progesterone | Progesterone, Micronized | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Levemir | Insulin Detemir | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $173.78 · 10 records | PFIZER INC. | ELIQUIS, GEMTESA, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, UBRELVY, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error